Prescient Therapeutics Limited (AU:PTX) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Prescient Therapeutics Limited has received FDA clearance to proceed with a Phase 2 trial of PTX-100, a promising Ras pathway inhibitor for treating relapsed and refractory cutaneous T-cell lymphomas. This approval marks a significant step for the company, building on encouraging Phase 1b data showing a 42% overall response rate among patients. The trial will be conducted at 15 global sites, potentially paving the way for a breakthrough in cancer therapy.
For further insights into AU:PTX stock, check out TipRanks’ Stock Analysis page.